Akari Therapeutics Plc
corporate_fare Company Profile
Akari Therapeutics Plc (NASDAQ:AKTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for AKTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for AKTX spans 8-K, 10-Q, S-3/A, S-3.
Recent high-impact activity:
- Akari Q3: $5.7M Cash, GLP Tox Started for AKTX-101, Phase 1 Targeted Mid-2027
- Q3 Cash of $5.7M Leaves Akari With Runway Only Into Q1 2027
- Akari 10-Q: Going-Concern Warning With $5.7M Cash and $24.1M Nine-Month Loss
- Akari's AKTX-101 Shows Robust Anti-Tumor Activity in Preclinical Urothelial Cancer Models
- Akari Therapeutics Q2 2026: Wider Loss, $7.7M Cash, Phase 1 Trial Set for Mid-2027
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 17,903 shares in AKTX as of the October 30, 2026 settlement, a 2.1% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of AKTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AKTX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-08.
Resale Registration Details · Deeply Discounted Warrants
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →